INmune Bio INMB 深 滬
已收盤 08-07 16:00:00 美东时间
2.085
+0.175
+9.16%
華盛通- 最 高2.105
- 今 開1.97
- 成交量 95.30万股
- 最 低 1.92
- 昨 收 1.91
- 總市值 5543.03万
- 52周最高 2.58
- 市盈率 靜 --
- 換手率 3.58%
- 52周最低 1.09
- 委 比 50.75%
- 總股本 2658.53万
- 歷史最高 30.37
- 量 比 2.98
- 振 幅 9.69%
- 歷史最低 1.09
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多INmune Bio Strengthens Cash Runway With R&D Rebates
Inmune Bio ( ($INMB) ) just unveiled an announcement. On July 30, 2026, INmune ...
08-01 04:33
INmune Bio Receives ~$4.2M Development Cash Rebate From Australia
This rebate is in addition to approximately $0.4 million of rebate from the United Kingdom during June 2026. After adjusting second-quarter operating cash flows to exclude the approximately $0.4 million rebate received during the quarter, the combined rebate proceeds exceeded the Company's net cash...
07-31 19:03
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
INmune Bio Inc. has formed a Scientific Advisory Board (SAB) to support the late-stage development of Ebstrocel™ for recessive dystrophic epidermolysis bullosa (RDEB) and expand the CORDStrom™ mesenchymal stromal cell (MSC) platform to target new disease indications. The SAB, chaired by Professor Mark Lowdell, includes leading experts in MSC biology, clinical translation, and rare diseases. The board will advise on regulatory strategies, clinical...
07-30 11:00
INmune Bio Reaches Manufacturing Milestone with First Commercial-Ready CORDStrom Umbilical Cord Tissue Processed At CGT Catapult In Partnership With Anthony Nolan Cord Blood Bank
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio In...
07-20 19:17
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio Inc. announced a significant manufacturing milestone for its CORDStrom™ platform, successfully processing its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult Manufacturing Innovation Centre in Stevenage, UK. This achievement enables the company to generate master cell banks (MCBs) for Ebstrocel™, its investigational product for recessive dystrophic epidermolysis bullosa (RDEB), meeting MHRA, EMA, and ...
07-20 11:00
INmune Bio To Present New Imaging Data From Phase 2 Study Of XPro In Patients With Early Alzheimer’s Disease At AAIC
Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition. White matter myelin integrity demonstrated a statistically significant treatment difference at Week ...
07-09 19:03
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
INmune Bio announced new imaging data from its Phase 2 study of XPro in early Alzheimer's disease, showing statistically significant treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24. These findings, presented at the Alzheimer’s Association International Conference (AAIC), demonstrate early effects on brain microstructure using two independent MRI techniques. Larger effects were observed in patients...
07-09 11:00
INmune Bio Executes Warrant Inducement and Extension Agreement
Inmune Bio ( ($INMB) ) has provided an announcement. On June 30, 2026, INmune B...
07-01 19:50
The UK Medicines & Healthcare Products Regulatory Agency Approves The Pediatric Investigation Plan For INmune Bio's Ebstrocel For Recessive Dystrophic Epidermolysis Bullosa
INmune Bio Inc. (NASDAQ:INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Pediatric Investigation Plan (PIP) for Ebstrocel™ for the treatment of Reces...
06-25 19:13
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
INmune Bio received MHRA alignment on CMC, non-clinical, and clinical strategies for Ebstrocel™ in RDEB, clearing a regulatory path for its 2026 UK MAA submission. MHRA recognized MissionEB Phase 2 data showing significant symptomatic benefits, particularly pain and pruritus, supporting chronic or intermittent therapy positioning. The agency also provided guidance on confirmatory Phase 3 trial design, evidence package, and manufacturing transitio...
06-23 12:00
